Results 101 to 110 of about 55,457 (267)
, 2018 E Gabriela Chiorean,1 Daniel Von Hoff,2 Yin Wan,3 Sandra Margunato-Debay,4 Marc Botteman,3 David Goldstein5 1Medical Oncology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, 2Oncology, Translational Genomics Research ...
Margunato-Debay S +5 more
core
Journal of Clinical and Translational Science, 2017 OBJECTIVES/SPECIFIC AIMS: Patients with locally advanced pancreatic cancer typically have poor outcomes, with a median survival of ~16 months. Novel methods to improve local control are needed.
Jacob Ezra Shabason +24 more
doaj +1 more source
Evaluation of combination treatment benefits of nab-paclitaxel in experimental pancreatic cancer.
, 2012 170 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human cancers and is characterized by early tissue invasion, metastasis and high resistance to systemic therapies.
Changhua Zhang +4 more
core +1 more source
Nutrition in Clinical Practice, EarlyView.Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen +6 more
wiley +1 more source
nab-Paclitaxel: Novel Clinical and Experimental Evidence in Pancreatic Cancer
, 2014 The past few decades have seen virtually no treatment advances for patients with metastatic pancreatic cancer. Clinical hallmark features of pancreatic ductal adenocarcinoma (PDA) include late symptom onset, invasive growth, early liver and lymph node ...
Neesse, A. +3 more
core +1 more source
Natural Products as Modulators of ABC Transporters in Breast Cancer
Phytotherapy Research, EarlyView.ABSTRACT Breast cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in early detection and treatment. Multidrug resistance (MDR), particularly in aggressive subtypes like triple‐negative breast cancer (TNBC), continues to hinder effective therapy.
Yoganishalini Sagadevan +2 more
wiley +1 more source
Nab-paclitaxel in Treatment of Metastatic Breast Cancer
Medical alphabet, 2019 Despite the development of new systems for the treatment of metastatic breast cancer (mBC), chemotherapy remains an integral and significant stage of treatment for any molecular tumor subtype. In accordance with modern concepts, the optimal strategy of therapy in the vast majority of cases of mBC is the sequential administration of cytostatics in mono ...
E. I. Kovalenko, E. V. Artamonova
openaire +2 more sources
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. [PDF]
BACKGROUND To determine whether the combination of nab-paclitaxel with gemcitabine has activity in patients with pretreated soft tissue sarcoma (STS).
Digklia, A. +23 more
core +1 more source
Phytotherapy Research, EarlyView.ABSTRACT Radioresistance remains a key barrier in breast cancer (BC) treatment. Baicalein, a flavonoid from Scutellaria baicalensis, has shown potential to enhance radiosensitivity. This study investigates its efficacy and mechanism in radioresistant BC models. Radioresistant BC cell models were established via fractionated irradiation and validated by
Zitong Zhao +3 more
wiley +1 more source
, 2020 Compliance with Ethical StandardsFunding The preparation of this review was not supported by any external funding.Conflicts of interest Connie Kang and Yahiya Y.
Connie Kang (7248215) +1 more
core +1 more source